Medipharm Labs Corp
TSX:LABS
Net Margin
Medipharm Labs Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CA |
|
Medipharm Labs Corp
TSX:LABS
|
29.1m CAD |
-17%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.4B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.6B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.8B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
159.6B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.2B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.1B USD |
13%
|
Medipharm Labs Corp
Glance View
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Medipharm Labs Corp's most recent financial statements, the company has Net Margin of -17.4%.
You don't have any saved screeners yet